-
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25 Jun 2025 08:00 GMT
… indicated for severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines …
-
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07 May 2025 20:45 GMT
… indicated for severe persistent allergic asthma and chronic rhinosinusitis with nasal … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines …
-
Alvotech Reports Record Results for 2024 and Provides Business Update
26 Mar 2025 22:34 GMT
… treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal … indicated for severe persistent allergic asthma and chronic rhinosinusitis with nasal … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, …
-
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26 Mar 2025 08:30 GMT
… treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal … indicated for severe persistent allergic asthma and chronic rhinosinusitis with nasal … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, …
-
China In-Focus: Regulators Clear Lotus Pharmaceuticals Asthma Drug For Clinical Trials
30 Apr 2010 17:14 GMT
… drugs, said that its asthma drug Laevo-Bambuterol has … than Bambuterol, a popular asthma drug currently on the … 2013-2014.
China-based Lotus Pharmaceuticals operates its business through … of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang …
-
Han Named Head Of OTC Unit At Lotus Pharmaceuticals
11 Dec 2009 16:17 GMT
… 11, 2009 (FinancialWire) — Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) a developer … ;
<p>China-based Lotus Pharmaceuticals operates Liang Fang Pharmaceutical and … treatment of cerebro-cardiovascular disease, asthma, and diabetes.</p …
-
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
03 Oct 2023 12:45 GMT
… such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines …
-
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
03 Oct 2023 09:00 GMT
… such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps … and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines …
About
© 1995-2025